RedHill Biopharma Ltd. (RDHL)
RDHL Stock Price Chart
Explore RedHill Biopharma Ltd. interactive price chart. Choose custom timeframes to analyze RDHL price movements and trends.
RDHL Company Profile
Discover essential business fundamentals and corporate details for RedHill Biopharma Ltd. (RDHL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
7 Jan 2013
Employees
35.00
Website
https://www.redhillbio.comCEO
Dror Ben-Asher
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
RDHL Financial Timeline
Browse a chronological timeline of RedHill Biopharma Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 14 Jun 2025
Earnings released on 10 Apr 2025
Earnings released on 3 Oct 2024
EPS came in at $900.00 .
Earnings released on 29 Aug 2024
EPS came in at -$200.00 falling short of the estimated -$30.00 by -566.67%.
Stock split effective on 20 Aug 2024
Shares were split 1 : 25 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Apr 2024
Earnings released on 12 Feb 2024
EPS came in at -$0.20 falling short of the estimated -$0.03 by -566.67%.
Earnings released on 29 Dec 2023
Earnings released on 30 Jun 2023
EPS came in at $4.83 , while revenue for the quarter reached $1.80M , missing expectations by -15.00%.
Earnings released on 12 Jun 2023
EPS came in at $146.75 , while revenue for the quarter reached $3.60M , missing expectations by -0.58%.
Earnings released on 27 Mar 2023
EPS came in at $1.07 , while revenue for the quarter reached $12.80M , missing expectations by -27.09%.
Stock split effective on 23 Mar 2023
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Nov 2022
EPS came in at -$2.00 falling short of the estimated -$0.30 by -566.67%, while revenue for the quarter reached $17.55M , missing expectations by -18.37%.
Earnings released on 23 Sept 2022
EPS came in at -$10.04 , while revenue for the quarter reached $18.35M , missing expectations by -14.67%.
Earnings released on 23 Jun 2022
EPS came in at -$3.00 surpassing the estimated -$4.00 by +25.00%, while revenue for the quarter reached $18.24M , missing expectations by -22.73%.
Earnings released on 17 Mar 2022
EPS came in at -$5.00 falling short of the estimated -$4.00 by -25.00%, while revenue for the quarter reached $22.07M , missing expectations by -8.37%.
Earnings released on 30 Nov 2021
EPS came in at -$4.60 surpassing the estimated -$4.80 by +4.17%, while revenue for the quarter reached $21.61M , missing expectations by -11.87%.
Earnings released on 26 Aug 2021
EPS came in at -$6.20 falling short of the estimated -$4.00 by -55.00%, while revenue for the quarter reached $21.50M , missing expectations by -20.36%.
Earnings released on 27 May 2021
EPS came in at -$5.30 falling short of the estimated -$4.60 by -15.22%, while revenue for the quarter reached $20.58M , missing expectations by -40.04%.
Earnings released on 18 Mar 2021
EPS came in at -$7.00 falling short of the estimated -$4.50 by -55.56%, while revenue for the quarter reached $21.46M .
Earnings released on 12 Nov 2020
EPS came in at -$5.00 falling short of the estimated -$2.20 by -127.27%, while revenue for the quarter reached $20.94M .
RDHL Stock Performance
Access detailed RDHL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.